ArticleThe New England journal of medicine2019
Teplizumab in Relatives at Risk for Type 1 Diabetes. Reply.
Article in The New England journal of medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pediatric Endocrine Society Statement on Considerations for Use of Teplizumab (Tzield™) in Clinical Practice.Hormone research in paediatrics · 2025Guideline
- Natural history study of type 1 diabetes risk in adults (T1DRA): protocol for screening and follow-up of UK adults.BMJ open · 2026Article
- Is the NOD mouse a good model for type 1 diabetes?Diabetologia · 2026Review
- Review
- Untangling the genetics of beta cell dysfunction and death in type 1 diabetes.Molecular metabolism · 2024Review
- Prioritizing Early Disease Intervention.Therapeutic innovation & regulatory science · 2023Article
- Review
- Two-age islet-autoantibody screening for childhood type 1 diabetes: a prospective cohort study.The lancet. Diabetes & endocrinology · 2022Article
- Editing T cell repertoire by thymic epithelial cell-directed gene transfer abrogates risk of type 1 diabetes development.Molecular therapy. Methods & clinical development · 2022Article
- EarLy Surveillance for Autoimmune diabetes: protocol for a qualitative study of general population and stakeholder perspectives on screening for type 1 diabetes in the UK (ELSA 1).BMJ open diabetes research & care · 2022Article
- Pre-RA: Can early diagnosis lead to prevention?Best practice & research. Clinical rheumatology · 2022Review
- Biomarkers of autoimmunity and beta cell metabolism in type 1 diabetes.Frontiers in immunology · 2022Review
- A phase 1b open-label dose-finding study of ustekinumab in young adults with type 1 diabetes.Immunotherapy advances · 2022Article
- Detecting insulitis in type 1 diabetes with ultrasound phase-change contrast agents.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Improving Prediction of Risk for the Development of Type 1 Diabetes-Insights From Populations at High Risk.Diabetes care · 2021Article
- Preclinical rheumatoid arthritis and rheumatoid arthritis prevention.Current opinion in rheumatology · 2020Review
Corrections and comments
- Comment on
- Comment on
- Comment on
Authors and funding
4 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
31693818What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.